WILLIAM ROSE - 08 Jun 2022 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role
Director, Member of 10% owner group, 10%+ Owner
Signature
/s/ Charles E. Gale, attorney-in-fact for William E. Rose
Issuer symbol
N/A
Transactions as of
08 Jun 2022
Net transactions value
+$79,987
Form type
4
Filing time
10 Jun 2022, 16:30:34 UTC
Previous filing
14 Jun 2021
Next filing
09 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Stock Option (right-to-buy) Award $0 +11,240 $0.000000 11,240 08 Jun 2022 Class A common stock 11,240 $34.76 Direct F1
transaction RETA Stock Option (right-to-buy) Award $79,987 +3,330 $24.02* 3,330 08 Jun 2022 Class A common stock 3,330 $34.76 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023 and June 7, 2023, subject to continued service through each vesting date.
F2 These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $80,000.